Table 3.
Change in Function and Other Symptom Outcomes (n = 10).
| Measure | Baseline, Mean (SD) | Week 8, Mean (SD) | P Valuea |
|---|---|---|---|
| Clinical functional measures | |||
| Functional Reach (cm) | 20.87 (5.81) | 36.92 (6.82) | .001a |
| Sit and Reach (cm) | 13.01 (5.75) | 23.94 (7.68) | .006a |
| Timed Up and Go (s) | 9.50 (3.11) | 6.44 (3.38) | .004a |
| Patient-reported outcomes | |||
| Perceived Stress Scale | 18.8 (7.61) | 14.8 (8.56) | .56 |
| Brief Pain Inventory (BPI) items (Pain Severity) | 4.835 (1.92) | 2.9 (1.97) | .041a |
| BPI items (Pain Interference) | 4.769 (2.13) | 3.175 (2.07) | .011a |
| FACT-NTX-Total | 95.9 (22.0) | 104.4 (27.3) | .445 |
| Patient Neuropathy Questionnaire | 6.8 (1.47) | 5.3 (1.49) | .003a |
| Falls Efficacy Scale | 32.7 (11.96) | 28.8 (10.88) | .072 |
| FACIT-SP | 103 (26.7) | 110 (33.8) | .510 |
| Pittsburgh Sleep Quality Index (PSQI) | 10.5 (4.81) | 8.9 (4.93) | .238 |
| Clinician-measured biomarkers | |||
| Vibration | |||
| Right midplantar (µV) | 30.60 (15.2) | 28.65 (17.2) | .634 |
| Left midplantar (µV) | 29.70 (15.5) | 27.25 (17.6) | .533 |
| Right great toe (µV) | 33.1 0 (10.6) | 24.9 (9.9) | .035a |
| Left great toe (µV) | 33.75 (14.4) | 25.55 (14.6) | .088 |
| Stress measure | |||
| Cortisol (µg/dL) | 0.131 (0.06) | 0.118 (0.6) | .116 |
Abbreviations: FACIT-SP, Functional Assessment of Chronic Illness Therapy—Spiritual Well-being Scale; FACT-NTX, Functional Assessment of Cancer Therapy—Neurotoxicity; PSQI, Pittsburgh Sleep Quality Index.
a
P < .05 significance level.